Fei Li

Mr. Fei Li

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
姗吴姗姗 吴
姗姗 吴
XZXiaoping Zhou
Xiaoping Zhou
Fei LiFei Li
Fei Li
SWSun Wei
Sun Wei
QZQing-Chuan Zheng
Qing-Chuan Zheng
DLDi Liang
Di Liang
In this study, we designed two series of novel anthraquinone-based benzenesulfonamide derivatives and their analogues as potential carbonic anhydrase inhibitors (CAIs) and evaluated their inhibitory activities against off-target human carbonic anhydrase II (hCA II) isoform and tumor-associated human carbonic anhydrase IX (hCA IX) isoform. Most of these compounds exhibited good inhibitory activities against hCA II and IX. The compounds that exhibited the best hCA inhibition were further studied against the MDA-MB-231, MCF-7, and HepG2 cell lines under hypoxic and normoxic conditions. Additionally, the compounds exhibiting the best antitumor activity were subjected to apoptosis and mitochondrial membrane potential assays, which revealed a significant increase in the percentage of apoptotic cells and a notable decrease in cell viability. Molecular docking studies were performed to demonstrate the presence of numerous hydrogen bonds and hydrophobic interactions between the compounds and the active site of hCA. Absorption, distribution, metabolism, excretion (ADME) predictions showed that all of the compounds had good pharmacokinetic and physicochemical properties.

14 September 2024 in Antibiotics
Verified
Journal Article
Open access
PDF file
DLDi Liang
Di Liang
Fei LiFei Li
Fei Li
DJDuan Jingzhong
Duan Jingzhong
SWSun Wei
Sun Wei
XYXiaoyan Yu
Xiaoyan Yu
Norfloxacin (NORF) is a broad-spectrum quinolone that is widely utilized for the treatment of various bacterial infections and is considered one of the most commonly used fluoroquinolone antibiotics. However, NORF’s clinical utility is limited by its poor water solubility and relatively low oral bioavailability. This study presents an optimization and synergistic enhancement approach through salt/co-crystal, aiming to maximize the biopharmaceutical properties of NORF with the use of phenolic acid. Following this strategy, two new hydrate salts of NORF with phenolic acid, namely, NORF—3,5-DBA hydrate (salt 1) and NORF—VA hydrate (salt 2), were prepared and systematically confirmed. Two hydrate salts were produced by means of the slow evaporation crystallization method, and the structures were determined through single-crystal X-ray diffraction (SCXRD). Additionally, powder X-ray diffraction (PXRD), Fourier-transform infrared (FT-IR) spectroscopy, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and high-performance liquid chromatography (HPLC) were applied to analyze the features of the two salts. The experimental results indicated that the formation of the two salts could enhance the solubility and improve the release behavior of NORF. Interestingly, the physicochemical properties of NORF were significantly improved as a result, leading to an enhancement in its antibacterial activity. This was demonstrated by the enhanced inhibition of bacterial strains and the lower minimum inhibitory concentration values.

20 June 2024 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
Fei LiFei Li
Fei Li
JXJi-Xiang Xiao
Ji-Xiang Xiao
LGLina Gao
Lina Gao
C21H19ClO3, orthorhombic, P212121 (no. 19), a = 6.0384(3) Å, b = 11.5696(7) Å, c = 24.6624(14) Å, V = 1722.96(17) Å3, Z = 4, Rgt (F) = 0.0253, wRref (F 2) = 0.0637, T = 100(2) K.